Brooks Laboratories IPO
Brooks Laboratories IPO — date, price band, lot size & details 2011
Brooks Laboratories listed on 5 Sep 2011 at ₹100, flat to the ₹100 issue price.
Brooks Laboratories is a pharmaceutical contract research and manufacturing company making critical care injectables and other dosage forms at Baddi. Its total income was Rs 53.20 crore in FY2011.
Stock price
Brooks Laboratories is listed — here is the live share price.
Timetable
Key dates from opening to listing. Today is 22 November.
- Open 16 Aug 2011
- Close 18 Aug 2011
- Allotment 26 Aug 2011
- Refund/credit TBA
- Listing 05 Sep 2011
Issue summary
The terms of the offer, as filed.
| IPO Dates | 16 to 18 Aug, 2011 |
|---|---|
| Price Band | ₹90 – ₹100 |
| Face Value | ₹10 |
| Lot Size | 60 Shares |
| Issue Size | ₹63 Cr |
| Sale Type | Fresh capital only |
| Listing On | BSE, NSE |
| Registrar | MUFG Intime India Private Limited |
| Min Investment | ₹ 6,000 |
Share of the offer set aside for each investor category, as stated in the offer document.
What will it cost me?
Bidding is in multiples of 60 shares at the ₹100 cut-off. Drag to size your application.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 60 | ₹6,000 |
| Retail (max) | 33 | 1,980 | ₹1,98,000 |
| S-HNI (min) | 34 | 2,040 | ₹2,04,000 |
| S-HNI (max) | 166 | 9,960 | ₹9,96,000 |
| B-HNI (min) | 167 | 10,020 | ₹10,02,000 |
Strengths & risks
Drawn from the offer document — the case for and against, side by side.
Strengths · 4
- 01Total income rose from Rs 43.83 crore in FY2009 to Rs 53.20 crore in FY2011.
- 02Profit after tax rose from Rs 2.96 crore in FY2009 to Rs 6.89 crore in FY2011.
- 03Total borrowing fell from Rs 16.06 crore in FY2009 to Rs 8.67 crore in FY2011.
- 04Rs 19.94 crore of the issue was for plant and machinery at a new facility.
Risks · 5
- 01It is small, with net worth of Rs 18.93 crore in FY2011, against an issue of Rs 63 crore.
- 02Contract manufacturing income depends on clients' orders, which can shift between suppliers; total income was Rs 53.20 crore in FY2011.
- 03Building a new plant with Rs 12.20 crore of construction carries execution and approval risk.
- 04Injectables plants face strict regulatory inspections, and it has a single unit at Baddi; it needed Rs 5.00 crore of working capital.
- 05Promoter holding fell from 99.5% before the issue to 60.77% after it.
Three years of numbers
All figures in ₹ crore, as reported in the Brooks Laboratories offer document.
| Metric | 31 Mar 2011 | 31 Mar 2010 | 31 Mar 2009 |
|---|---|---|---|
| Total Income | 53.20 | 45.45 | 43.83 |
| Profit After Tax | 6.89 | 5.20 | 2.96 |
| NET Worth | 18.93 | 13.57 | 8.37 |
| Reserves and Surplus | 9.48 | 8.89 | 5.77 |
| Total Borrowing | 8.67 | - | 16.06 |
See how this IPO compares — view listing performance of all mainboard IPOs.
Valuation & key ratios
Ratios are for the latest full financial year reported in the Brooks Laboratories RHP.
Where the money goes
₹62.99 Cr of the issue is earmarked to named objects.
About the company
It makes a wide range of products for the critical care segment, including beta lactam, cephalosporin and general dry powder injectables, ampoules and liquid vials, dry syrups and tablets.
Its manufacturing unit is at Baddi in Himachal Pradesh.
The IPO was Rs 63 crore and was entirely fresh issue at Rs 100, the top of the Rs 90 to Rs 100 band. Most of the money was for a new plant, covering land, buildings, machinery and utilities.
Interested in this IPO? Check the live subscription status or browse all upcoming mainboard IPOs.
The bankers & the filings
Who is running the book, and the documents this page is built from.
Brooks Laboratories IPO Documents
Read the filings this page is built from.
Lead Manager Track Record
How the book-running lead managers on this issue have priced their past IPOs, measured on listing day.
D And A Financial Services Private Ltd
3 issues handledBest listing: Shilpi Cable Technologies (+13.0%). Weakest: Alpine Texworld (0.0%).
Listing gain compares the listing-day opening price with the issue price, using the IPOs on IPO Guru that this lead manager has taken to market. A strong record reflects how the banker has priced past issues — it is not a forecast for this one. See every issue they have handled on the lead managers page.
Company contact
Frequently asked
What is the GMP of Brooks Laboratories?
The current Grey Market Premium is ₹0.
What is the Brooks Laboratories IPO price band?
₹90 to ₹100, on a face value of ₹10.
When is the allotment?
The basis of allotment is 26 August 2011, with listing on 5 September 2011.
How do I check allotment status?
On the IPO Guru allotment page or on the registrar's site — MUFG Intime India Private Limited.
Every number here traces back to a filing.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Every number on this page is sourced from the RHP, BSE & NSE.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.